Raloxifene Treatment Is Associated With Increased Serum Estradiol and Decreased Bone Remodeling in Healthy Middle-Aged Men With Low Sex Hormone Levels
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
In healthy middle-aged men, raloxifene treatment was associated with increased serum estradiol and decreased biochemical markers of bone turnover in subjects with estradiol levels below a threshold of 101.8 pM. Introduction: We investigated the effects of the selective estrogen receptor modulator raloxifene on bone remodeling in healthy middle-aged men. Materials and Methods: Forty-three healthy eugonadal men (mean age, 56 years; range, 49-70 years) were enrolled in a randomized placebo-controlled, double-blind, two-sequence crossover study. The subjects received either raloxifene 120 mg/day or placebo for 6 weeks, followed by a 2-month washout period, before crossing over. To predict changes of urinary total deoxypyridinoline/creatinine on raloxifene treatment, we used a logistic regression model to determine cut-off values of sex hormones for highest sensitivity and specificity. Results: In the whole group, raloxifene treatment was associated with an increase in serum sex hormones, that is, total testosterone (+13%, p < 0.01), bioavailable testosterone (+11%, p = 0.02), total estradiol (+11%, p < 0.002), and bioavailable estradiol (+11%, p = 0.035), and with a decrease in serum osteocalcin (−13%, p < 0.05) and serum total alkaline phosphatase (−6%, p < 0.05). Other biochemical markers of bone turnover remained unchanged. Using a logistic regression model to predict changes in urinary deoxypyridoline, we calculated thresholds for total (101.8 pM) and bioavailable (4.79 pM) estradiol, as well as for total (19.4 nM) and bioavailable (0.35 nM) testosterone. Raloxifene treatment was associated with an increase in serum estradiol and decrease in biochemical markers of bone turnover in men with estradiol values below these estradiol thresholds, without any significant change in subjects with values above them. Similarly, raloxifene treatment was associated with an increase in serum testosterone and a decrease in biochemical markers of bone turnover in those with baseline testosterone values below the testosterone thresholds. The association between antiresorptive effects of raloxifene and low sex hormone levels was more pronounced for estradiol than for testosterone. Conclusions: The antiresorptive effect of raloxifene was only detectable in men with low baseline estradiol levels. Unlike in postmenopausal women, the increase of estradiol may contribute to the antiresorptive effect of raloxifene in men.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Estrogen Resistance Caused by a Mutation in the Estrogen-Receptor Gene in a Man
Smith, E. P., Boyd, J., Frank, G. R., Takahashi, H., Cohen, R. M., Specker, B., Williams, T. C., Lubahn, D. B., & Korach, K. S. (1994) · New England Journal of Medicine · doi:10.1056/nejm199410203311604 · Cited by 2,471 · cited 1×
“A marked decrease of BMD with unfused epiphyses has been shown in adult men with a defect in the estrogen receptor.((6)) A similar skeletal defect is seen in male with a genetic defect in aromatase enzyme activity((7)); the skeleton in this case is fully responsive to exogenous estrogen.”
BackgroundMorishima, A., Grumbach, M. M., Simpson, E. R., Fisher, C., & Qin, K. (1995) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.80.12.8530621 · Cited by 1,416 · cited 1×
“A similar skeletal defect is seen in male with a genetic defect in aromatase enzyme activity((7)); the skeleton in this case is fully responsive to exogenous estrogen.”
BackgroundEffect of testosterone and estradiol in a man with aromatase deficiency
Carani, C., Qin, K., Simoni, M., Faustini-Fustini, M., Serpente, S., Boyd, J., Korach, K. S., & Simpson, E. R. (1997) · New England Journal of Medicine · doi:10.1056/nejm199707103370204 · Cited by 1,151 · cited 1×
“A similar skeletal defect is seen in male with a genetic defect in aromatase enzyme activity((7)); the skeleton in this case is fully responsive to exogenous estrogen.((8,9)) In observational cross-sectional and longitudinal studies, serum estrogens, but not androgens, levels are positive predictors of BMD in men.”
BackgroundFalahati-Nini, A., Riggs, B. L., Atkinson, E. J., O’Fallon, W. M., Eastell, R., & Khosla, S. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10942 · Cited by 757 · cited 1×
“Finally, estrogen, but not testosterone, supplementation prevents the increased bone resorption resulting from gonadotropin-releasing hormone (GnRH)-induced hypogonadism and aromatase inhibition.((19)) The aims of this study were to evaluate the effects of raloxifene on sex hormone levels and their relationships with…”
BackgroundKhosla, S. (2001) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.86.8.3555 · Cited by 522
Slemenda, C. W., Longcope, C., Zhou, L., Hui, S. L., Peacock, M., & Johnston, C. C. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119701 · Cited by 455
Khosla, S. (1998) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.83.7.2266 · Cited by 447
Estrogen and the Male Skeleton
Khosla, S., Melton, L. J., & Riggs, B. L. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.4.8417 · Cited by 308 · cited 5×
“These findings also support a pivotal role for estrogen in skeletal metabolism in men and are supported by the results of recent clinical studies.((5)) As in postmenopausal women, the antiresorptive effect of raloxifene in men could be caused by a direct estrogen receptor–mediated effect on the skeletal system.”
BackgroundResultInfluentialHormonal and Biochemical Parameters in the Determination of Osteoporosis in Elderly Men*
Center, J. R., Nguyen, T. V., Sambrook, P. N., & Eisman, J. A. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.10.6051 · Cited by 189
Bioavailable Estradiol May Be an Important Determinant of Osteoporosis in Men: The MINOS Study
Szulc, P. (2001) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.86.1.192 · Cited by 169
Cited by
Estrogens and androgens in skeletal physiology and pathophysiology
Almeida, M., Laurent, M. R., Dubois, V., Claessens, F., O'Brien, C. A., Bouillon, R., Vanderschueren, D., & Manolagas, S. C. (2017) · Physiological Reviews · doi:10.1152/physrev.00033.2015 · Cited by 860
Sartorius, G. A., Ly, L. P., & Handelsman, D. J. (2014) · The Journal of Sexual Medicine · doi:10.1111/jsm.12550 · Cited by 44
Metadata
- Authors
- Uebelhart, B., Herrmann, F., Pavo, I., Draper, M. W., & Rizzoli, R.
- Venue
- Journal of Bone and Mineral Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2004-09-01
- Volume
- 19
- Issue
- 9
- Pages
- 1518-1524
- ISSN
- 0884-0431 (ISSN-L)
- 1523-4681
- OpenAlex
- W2002975750
- Cited by
- 54
- References
- 11
- FWCI
- 2.48
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.